**4. Conclusion**

Hereditary DCM is a heterogeneous condition, which may lead to advanced HF as well as SCD. Risk stratification and preventive management strategies are challenging. Many factors must be considered in the management of patients with

**165**

*Sudden Cardiac Death in Hereditary Dilated Cardiomyopathy*

hereditary DCM. Gene mutations are surfacing and have already been proven to play a very significant role in clinical decisions. Moreover, based on new data and studies, the profile of each DCM patient tends to be better understood. As a result, both therapy and prevention evolve and ameliorate in a way that will become individualized. ICDs are lifesaving but their role in different genotypic settings remains

Peter Magnusson has received speaker fees or grants from Abbott, Alnylam, Bayer, AstraZeneca, Boehringer-Ingelheim, Lilly, MSD, Novo Nordisk, Octopus Medical, Pfizer, and Zoll. Joseph Pergolizzi is a principal at Native Cardio, Inc. Marianna Leopoulou and Jo Ann LeQuang have no relevant disclosures.

*DOI: http://dx.doi.org/10.5772/intechopen.91702*

to be elucidated.

**Conflicts of interest**

**Acronyms and abbreviations**

ACE angiotensin converting enzyme ARB angiotensin receptor blocker

CMR cardiac magnetic resonance CRT cardiac resynchronization therapy

LGE late gadolinium enhancement

LVEF left ventricular ejection fraction NSVT nonsustained ventricular tachycardia

NYHA New York Heart Association

RBM20 RNA binding motif protein 20

DCM dilated cardiomyopathy

LMNA lamin A/C LV left ventricle

PLN phospholamban

TTN titin

SCD sudden cardiac death

VF ventricular fibrillation VT ventricular tachycardia

AR-DCM arrhythmogenic dilated cardiomyopathy

ICD implantable cardioverter defibrillator

RAAS renin-angiotensin-aldosterone system

SCN5A sodium voltage-gated channel alpha subunit 5

ARVC arrhythmogenic right ventricular cardiomyopathy

CRT-D cardiac resynchronization therapy defibrillator

*Sudden Cardiac Death in Hereditary Dilated Cardiomyopathy DOI: http://dx.doi.org/10.5772/intechopen.91702*

hereditary DCM. Gene mutations are surfacing and have already been proven to play a very significant role in clinical decisions. Moreover, based on new data and studies, the profile of each DCM patient tends to be better understood. As a result, both therapy and prevention evolve and ameliorate in a way that will become individualized. ICDs are lifesaving but their role in different genotypic settings remains to be elucidated.
